SpringWorks Therapeutics logo

SpringWorks TherapeuticsNASDAQ: SWTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 September 2019

Next earnings report:

12 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.35 B
-40%vs. 3y high
83%vs. sector
-vs. 3y high
-vs. sector
-47%vs. 3y high
78%vs. sector
-96%vs. 3y high
87%vs. sector

Price

regular market | 7 min ago
$31.59+$0.97(+3.17%)

Dividend

No data over the past 3 years
$59.73 M$53.17 M
$59.73 M-$39.92 M

Analysts recommendations

Institutional Ownership

SWTX Latest News

SpringWorks Therapeutics Merits A Speculative Buy
seekingalpha.com04 November 2024 Sentiment: -

Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead.

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
zacks.com06 September 2024 Sentiment: POSITIVE

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?

SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
zacks.com29 August 2024 Sentiment: POSITIVE

The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.

FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
globenewswire.com28 August 2024 Sentiment: POSITIVE

– PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
zacks.com23 August 2024 Sentiment: POSITIVE

Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
seekingalpha.com07 August 2024 Sentiment: POSITIVE

SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation.

SpringWorks Therapeutics (SWTX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.25 per share a year ago.

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com07 August 2024 Sentiment: POSITIVE

– Achieved $40.2 million in OGSIVEO ® (nirogacestat) net product revenue in the second quarter –

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
globenewswire.com29 July 2024 Sentiment: POSITIVE

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion.

SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
zacks.com12 July 2024 Sentiment: POSITIVE

SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.

  • 1(current)

What type of business is SpringWorks Therapeutics?

SpringWorks Therapeutics, Inc. is a biopharmaceutical company operating in the clinical stage. The company is focused on acquiring, developing, and commercializing medicines for patients suffering from rare diseases and oncological diseases. The company has a portfolio of oncology product candidates targeting small molecules, and other programs aimed at treating genetically defined types of cancer. It provides nirogacestat, which is an oral small molecule gamma-secretase inhibitor (GSI). It also provides mirdametinib, which is an oral low molecular weight MEK inhibitor. Mirdametinib is being developed for the treatment of plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN). SpringWorks Therapeutics, Inc. was founded in 2017, with its headquarters located in Stamford, Connecticut.

What sector is SpringWorks Therapeutics in?

SpringWorks Therapeutics is in the Healthcare sector

What industry is SpringWorks Therapeutics in?

SpringWorks Therapeutics is in the Biotechnology industry

What country is SpringWorks Therapeutics from?

SpringWorks Therapeutics is headquartered in United States

When did SpringWorks Therapeutics go public?

SpringWorks Therapeutics initial public offering (IPO) was on 13 September 2019

What is SpringWorks Therapeutics website?

https://www.springworkstx.com

Is SpringWorks Therapeutics in the S&P 500?

No, SpringWorks Therapeutics is not included in the S&P 500 index

Is SpringWorks Therapeutics in the NASDAQ 100?

No, SpringWorks Therapeutics is not included in the NASDAQ 100 index

Is SpringWorks Therapeutics in the Dow Jones?

No, SpringWorks Therapeutics is not included in the Dow Jones index

When was SpringWorks Therapeutics the previous earnings report?

No data

When does SpringWorks Therapeutics earnings report?

The next expected earnings date for SpringWorks Therapeutics is 12 November 2024